Plenary Session I Agenda

PRESIDER: Richard Gallo, MD/PhD

 

3:30 PM-3:45 PM

#506, Predicting the long-term outcomes of biologics in psoriasis patients using machine learning

1. S. Emam¹, A. Du², P. Surmanowicz², S. Thomsen¹, R. Griener¹, R. Gniadecki²

¹University of Alberta, Edmonton, Alberta, Canada, ²Medicine, University of Alberta, Edmonton, Alberta, Canada

 

3:45 PM-4:00 PM

#476, Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database

1. R. Conic^{1, 2}, R. Knackstedt², G. Damiani², B. Gastman²

¹University of Maryland, Baltimore, Maryland, United States, ²Cleveland Clinic, Cleveland, Ohio, United States

 

4:00 PM-4:15 PM

#130, Small non-coding RNAs interact with ERK2 and effect MAPK/ERK pathway

1. Z. Siprashvili¹, R. M. Shenoy¹, L. Elcavage¹, P. Khavari^{1, 2}

¹Dermatology, Stanford University, Stanford, California, United States, ²VA Palo Alto Healthcare System, Palo Alto, California, United States

 

4:15 PM-4:30 PM

#861, Intravenous gentamicin therapy for junctional epidermolysis bullosa patients harboring nonsense mutations

1. M. Hao¹, R. Antaya², J. Cogan¹, C. Hamilton², Y. Hou¹, A. Kwong¹, D. Woodley¹, M. Chen¹

¹University of Southern California, Los Angeles, California, United States, ²Yale School of Medicine, New Haven, Connecticut, United States

 

4:30 PM-4:45 PM

#361, Skin-induced IL-36 triggers plasma cell IgE class switching and allergic disease

1. G. J. Patrick¹, H. Liu¹, M. Alphonse¹, D. Dikeman¹, C. Youn¹, J. Otterson¹, Y. Wang¹, A. Ravipati¹, Q. Liu¹, E. Raymond², M. Ramanujam², N. Archer¹, L. S. Miller¹

¹Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland, United States, ²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, United States